EP2049135A4 - LACTOFERRINE AS RADIOPROTECTIVE AGENT - Google Patents

LACTOFERRINE AS RADIOPROTECTIVE AGENT

Info

Publication number: EP2049135A4
Authority: EP; European Patent Office
Prior art keywords: lactoferrine; radioprotective agent; radioprotective; agent
Prior art date: 2006-06-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP07784522A

Other languages

German (de)

French (fr)

Other versions

EP2049135A2 (en

Inventor

Atul Varadhachary

Karel Petrak

Paul Blezinger

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Agennix Inc

Original Assignee

Agennix Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-22

Filing date

2007-06-22

Publication date

2009-12-30

2007-06-22 Application filed by Agennix Inc filed Critical Agennix Inc

2009-04-22 Publication of EP2049135A2 publication Critical patent/EP2049135A2/en

2009-12-30 Publication of EP2049135A4 publication Critical patent/EP2049135A4/en

Status Ceased legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP07784522A 2006-06-22 2007-06-22 LACTOFERRINE AS RADIOPROTECTIVE AGENT Ceased EP2049135A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80554006P	2006-06-22	2006-06-22
PCT/US2007/071942 WO2007150049A2 (en)	2006-06-22	2007-06-22	Lactoferrin as a radioprotective agent

Publications (2)

Publication Number	Publication Date
EP2049135A2 EP2049135A2 (en)	2009-04-22
EP2049135A4 true EP2049135A4 (en)	2009-12-30

Family

ID=38834430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP07784522A Ceased EP2049135A4 (en)	2006-06-22	2007-06-22	LACTOFERRINE AS RADIOPROTECTIVE AGENT

Country Status (4)

Country	Link
EP (1)	EP2049135A4 (en)
CN (1)	CN101505781A (en)
CA (1)	CA2655331A1 (en)
WO (1)	WO2007150049A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201304041D0 (en) *	2013-03-06	2013-04-17	Water Jel Europ Llp	Treatment and prophylaxis of radiation dermatitis
CN111514280A (en) *	2020-06-15	2020-08-11	中国人民解放军西部战区总医院	Medicine for preventing radiodermatitis
CN111671885A (en) *	2020-06-15	2020-09-18	中国人民解放军西部战区总医院	Medicine for treating radiodermatitis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU645589B2 (en) *	1990-07-13	1994-01-20	Novozymes Biopharma Dk A/S	Growth-promoting agent
WO1996034614A1 (en) *	1995-05-02	1996-11-07	Gropep Pty. Ltd.	Method of preventing or treating alimentary tract damage due to chemotherapy or radiation
WO2001024812A1 (en) *	1999-10-06	2001-04-12	N.V. Nutricia	USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
WO2002092077A2 (en) *	2001-05-16	2002-11-21	N.V. Nutricia	Use of lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
WO2004060081A1 (en) *	2003-01-07	2004-07-22	N.V. Nutricia	A method of improving nutrient utilisation by a mammal and a composition for use therein
US20040214750A1 (en) *	2003-04-28	2004-10-28	Georgiades Izolda M.	Medicaments for healing skin conditions in humans
RU2005119153A (en) *	2005-06-21	2006-12-27	Федеральное государственное унитарное предпри тиеГосударственный научный центр - Институт биофизики Федерального медико-биологического агентства (RU)	MEANS OF TREATMENT OF ACUTE RADIATING DISEASE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5571697A (en)	1989-05-05	1996-11-05	Baylor College Of Medicine Texas Medical Center	Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5571691A (en)	1989-05-05	1996-11-05	Baylor College Of Medicine	Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
AU664561B2 (en)	1991-06-21	1995-11-23	University Of Cincinnati, The	Orally administrable therapeutic proteins and method of making
ZA932568B (en)	1992-04-24	1993-11-12	Baylor College Midecine A Non	Production of recombinant human lactoferrin
JP2002515893A (en)	1997-02-03	2002-05-28	ファーミングインテレクチュアルプロパティビーブイ	Useful properties of human lactoferrin and its variants
US20030203839A1 (en) *	1999-10-29	2003-10-30	Kruzel Marian L.	Immune enhancing composition containing lactoferrin
WO2006047744A2 (en) *	2004-10-26	2006-05-04	Agennix Incorporated	Compositions of lactoferrin related peptides and uses thereof

2007
- 2007-06-22 CN CN 200780030596 patent/CN101505781A/en active Pending
- 2007-06-22 EP EP07784522A patent/EP2049135A4/en not_active Ceased
- 2007-06-22 WO PCT/US2007/071942 patent/WO2007150049A2/en not_active Ceased
- 2007-06-22 CA CA002655331A patent/CA2655331A1/en not_active Abandoned

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU645589B2 (en) *	1990-07-13	1994-01-20	Novozymes Biopharma Dk A/S	Growth-promoting agent
WO1996034614A1 (en) *	1995-05-02	1996-11-07	Gropep Pty. Ltd.	Method of preventing or treating alimentary tract damage due to chemotherapy or radiation
WO2001024812A1 (en) *	1999-10-06	2001-04-12	N.V. Nutricia	USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
WO2002092077A2 (en) *	2001-05-16	2002-11-21	N.V. Nutricia	Use of lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
WO2004060081A1 (en) *	2003-01-07	2004-07-22	N.V. Nutricia	A method of improving nutrient utilisation by a mammal and a composition for use therein
US20040214750A1 (en) *	2003-04-28	2004-10-28	Georgiades Izolda M.	Medicaments for healing skin conditions in humans
RU2005119153A (en) *	2005-06-21	2006-12-27	Федеральное государственное унитарное предпри тиеГосударственный научный центр - Институт биофизики Федерального медико-биологического агентства (RU)	MEANS OF TREATMENT OF ACUTE RADIATING DISEASE

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ARTYM J ET AL: "Reconstitution of the cellular immune response by lactoferrin in cyclophosphamide-treated mice is correlated with renewal of T cell compartment", IMMUNOBIOLOGY, URBAN UND FISCHER VERLAG, DE, vol. 207, no. 3, 1 January 2003 (2003-01-01), pages 197 - 205, XP004954075, ISSN: 0171-2985, DOI: 10.1078/0171-2985-00233 *
BELINDA VAN'T LAND ET AL: "Lactoferrin Reduces Methotrexate-Induced Small Intestinal Damage, Possibly Through Inhibition of GLP-2-Mediated Epithelial Cell Proliferation", DIGESTIVE DISEASES AND SCIENCES, vol. 49, no. 3, 1 March 2004 (2004-03-01), pages 425 - 433, XP055010171, ISSN: 0163-2116, DOI: 10.1023/B:DDAS.0000020497.35250.93 *
BELJAARS L ET AL: "Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo", ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 63, no. 3, 1 September 2004 (2004-09-01), pages 197 - 208, XP004579999, ISSN: 0166-3542 *
FUJIHARA T ET AL: "Lactoferrin protects against UV-B irradiation-induced corneal epithelial damage in rats.", CORNEA MAR 2000, vol. 19, no. 2, March 2000 (2000-03-01), pages 207 - 211, XP008115199, ISSN: 0277-3740 *
J. ARTYM ET AL: "Lactoferrin Accelerates Reconstitution of the Humoral and Cellular Immune Response During Chemotherapy-induced Immunosuppression and Bone Marrow Transplant in Mice", STEM CELLS AND DEVELOPMENT, vol. 14, no. 5, 1 October 2005 (2005-10-01), pages 548 - 555, XP055008464, ISSN: 1547-3287, DOI: 10.1089/scd.2005.14.548 *
PIET DIRIX ET AL: "Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia", SUPPORTIVE CARE IN CANCER, SPRINGER-VERLAG, DE, vol. 15, no. 12, 18 January 2007 (2007-01-18), pages 1429 - 1436, XP019564647, ISSN: 1433-7339 *
See also references of WO2007150049A2 *
SUSUMU TERAGUCHI ET AL: "Protection against infections by oral lactoferrin: Evaluation in animal models", BIOMETALS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 17, no. 3, 1 June 2004 (2004-06-01), pages 231 - 234, XP019232200, ISSN: 1572-8773, DOI: 10.1023/B:BIOM.0000027697.83706.32 *
TERESA G HAYES ET AL: "Phase I trial of oral talactoferrin alfa in refractory solid tumors", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 24, no. 3, 20 September 2005 (2005-09-20), pages 233 - 240, XP019394384, ISSN: 1573-0646 *
VARADHACHARY ATUL ET AL: "Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 111, no. 3, 1 September 2004 (2004-09-01), pages 398 - 403, XP002538536, ISSN: 0020-7136, [retrieved on 20040423], DOI: 10.1002/IJC20271 *

Also Published As

Publication number	Publication date
CA2655331A1 (en)	2007-12-27
CN101505781A (en)	2009-08-12
WO2007150049A2 (en)	2007-12-27
EP2049135A2 (en)	2009-04-22
WO2007150049A3 (en)	2008-02-21

Legal Events

Date	Code	Title	Description
2009-03-20	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2009-04-22	17P	Request for examination filed	Effective date: 20090120
2009-04-22	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
2009-04-22	AX	Request for extension of the european patent	Extension state: AL BA HR MK RS
2009-06-17	RIN1	Information on inventor provided before grant (corrected)	Inventor name: BLEZINGER, PAUL Inventor name: PETRAK, KAREL Inventor name: VARADHACHARY, ATUL
2009-09-30	DAX	Request for extension of the european patent (deleted)
2009-12-30	A4	Supplementary search report drawn up and despatched	Effective date: 20091202
2010-04-28	17Q	First examination report despatched	Effective date: 20100330
2012-06-10	REG	Reference to a national code	Ref country code: DE Ref legal event code: R003
2012-09-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2012-10-17	18R	Application refused	Effective date: 20120610

Publication	Publication Date	Title
BRPI0916123A2 (en)	2015-11-03	"concentrated shampoo composition"
BRPI0810928A2 (en)	2019-09-24	"pharmaceutical composition"
EP2316414A4 (en)	2011-09-21	AFTER SHAMPOO COMPOSITION
BRPI0719626A2 (en)	2014-06-24	'' COMPOUND ''
EP2066689A4 (en)	2010-04-28	HYD1 PEPTIDES AS ANTICANCER AGENTS
EP2129709A4 (en)	2010-03-31	HYDROCHLOROFLUOROOLEFIN BLOWING AGENT COMPOSITIONS
EP2291078A4 (en)	2011-08-24	OXAZOLOBENZIMIDAZOLE DERIVATIVES
DK2068822T3 (en)	2012-01-23	Self-preserved aqueous pharmaceutical compositions
DK1998783T3 (en)	2014-08-04	Ophthalmic compositions comprising povidone iodine
EP2123158A4 (en)	2013-01-16	HERBICIDE COMPOSITION
EP2280916A4 (en)	2014-07-23	HYDROCHLOROFLUOROOLEFIN COMPOSITIONS
BRPI0913806A2 (en)	2015-10-20	"composition"
EP2038758A4 (en)	2011-08-24	INTEGRATED APPLICATION GATEWAY
EP2275504A4 (en)	2011-03-02	COATING AGENT COMPOSITION
EP2341933A4 (en)	2012-03-14	IMIDAZOQUINOLINE DERIVATIVES LIPIDATED
BRPI0922904A2 (en)	2018-05-29	"compounds"
EP2025337A4 (en)	2010-09-08	EXTERNAL PHARMACEUTICAL COMPOSITION
EP2076509A4 (en)	2011-02-16	AZACYCLOALCANE DERIVATIVES AS DELTA-9 DEATURASE STEAROYL COENZYME INHIBITORS
EP2332425A4 (en)	2015-07-15	AROMA ENHANCING AGENT
EP2005959A4 (en)	2012-12-26	EXTERNAL PHARMACEUTICAL COMPOSITION
EP2279532A4 (en)	2011-07-27	OXAZOLOBENZIMIDAZOLE DERIVATIVES
EP2005958A4 (en)	2010-09-15	EXTERNAL PHARMACEUTICAL COMPOSITION
EP2163603A4 (en)	2012-04-04	COMPOSITION OF A SURFACTANT AGENT
EP1951731A4 (en)	2010-07-07	AZACYCLOHEXANE DERIVATIVES AS DELTA-9 DEATURASE STÉAROYL-COENZYME INHIBITORS
DK2041128T3 (en)	2012-09-10	Substituted gamma-lactams as therapeutic agents